Literature DB >> 10758129

Differential effects of mu-, delta-, and kappa-opioid receptor agonists on mechanosensitive gastric vagal afferent fibers in the rat.

N Ozaki1, J N Sengupta, G F Gebhart.   

Abstract

Single-fiber recordings were made from the decentralized right cervical vagus nerve (hyponodosal) of the rat. A total of 56 afferent fibers that responded to gastric distension (GD) were studied: 6 fibers were stimulated by phasic balloon GD, 50 by fluid GD. All fibers gave increasing responses to increasing pressures of GD (5-60 mmHg). The effects of mu-opioid (morphine), delta-opioid (SNC80), and kappa-opioid (EMD61,753, U62,066) receptor agonists were tested on responses of afferent fibers to GD. Morphine, administered systemically over a broad dose range (10 microg to 31 mg/kg, cumulative), had no effect on either resting activity or responses of vagal afferent fibers to GD. Similarly, the delta-opioid receptor agonist SNC80 (0.05-3.2 mg/kg) did not affect resting activity or responses to GD. In contrast, cumulative intra-arterial doses of the kappa-opioid receptor agonist EMD61,753 or U62,066 dose dependently attenuated afferent fiber responses to GD. Doses producing inhibition to 50% of the control response to GD of EMD61,753 (8.0 mg/kg) and U62,066 (8.8 mg/kg) did not differ. The effect of U62,066 was moderately attenuated by a nonselective dose (4 mg/kg) of naloxone hydrochloride; the kappa-opioid receptor-selective antagonist nor-BNI (20 mg/kg) was ineffective. These results demonstrate that kappa-, but not mu- or delta-opioid receptor agonists modulate visceral sensation conveyed by vagal afferent fibers innervating the stomach. Given that kappa-opioid receptor agonists effects were only modestly antagonized by naloxone and not at all by nor-BNI, the results point to a novel site of action.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10758129     DOI: 10.1152/jn.2000.83.4.2209

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  15 in total

Review 1.  Treating irritable bowel syndrome: overview, perspective and future therapies.

Authors:  Michael Camilleri
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

2.  A population pharmacokinetic and pharmacodynamic study of a peripheral κ-opioid receptor agonist CR665 and oxycodone.

Authors:  Anne E Olesen; Kim Kristensen; Camilla Staahl; Sherron Kell; Gilbert Y Wong; Lars Arendt-Nielsen; Asbjørn M Drewes
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

Review 3.  Irritable bowel syndrome and chronic constipation: emerging drugs, devices, and surgical treatments.

Authors:  Lucinda A Harris; Stephanie Hansel; John DiBaise; Michael D Crowell
Journal:  Curr Gastroenterol Rep       Date:  2006-08

Review 4.  IBS--review and what's new.

Authors:  Amy Foxx-Orenstein
Journal:  MedGenMed       Date:  2006-07-26

5.  Modulation of gastro-oesophageal vagal afferents by galanin in mouse and ferret.

Authors:  Amanda J Page; James A Slattery; Tracey A O'donnell; Nicole J Cooper; Richard L Young; L Ashley Blackshaw
Journal:  J Physiol       Date:  2005-01-06       Impact factor: 5.182

Review 6.  Visceral pain.

Authors:  S K Joshi; G F Gebhart
Journal:  Curr Rev Pain       Date:  2000

Review 7.  Visceral analgesics: drugs with a great potential in functional disorders?

Authors:  Sylvie Bradesi; Jeremy Herman; Emeran A Mayer
Journal:  Curr Opin Pharmacol       Date:  2008-09-26       Impact factor: 5.547

8.  Treatment of Functional Dyspepsia.

Authors:  Silvia Delgado-Aros; Filippo Cremonini; Nicholas J. Talley
Journal:  Curr Treat Options Gastroenterol       Date:  2004-04

Review 9.  Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation.

Authors:  M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2008-09       Impact factor: 3.598

10.  Involvement of galanin receptors 1 and 2 in the modulation of mouse vagal afferent mechanosensitivity.

Authors:  Amanda J Page; James A Slattery; Stuart M Brierley; Arie S Jacoby; L Ashley Blackshaw
Journal:  J Physiol       Date:  2007-07-12       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.